Previous 10 | Next 10 |
Generally speaking, small-cap growth stocks probably aren't the first place you'd look to invest in during a particularly turbulent market. Underscoring this point, small caps were hit far harder than their mid- and large-cap peers during the height of the COVID-19-induced sell-off in March. Ho...
Satsuma Pharmaceuticals Inc. (NASDAQ: STSA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We had the opportunity to host a virtual fireside chat with the Satsuma Pharmaceuticals management team, including John Kollins (Preside...
Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Satsuma reported better-than expected 4Q19 EPS loss of ($0.62) vs our ($0.79), driven by lower OpEx of $11M vs our $15M. However, we be...
Satsuma Pharmaceuticals (NASDAQ: STSA ): Q4 GAAP EPS of -$0.62 beats by $0.20 . More news on: Satsuma Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
On track to announce topline data in second half of 2020 from Phase 3 EMERGE™ efficacy trial evaluating STS101 for the acute treatment of migraine Company well-capitalized with cash, cash equivalents, and marketable securities of $117.9 million at the end of 2019, providi...
Facing record-high volatility and market uncertainty, one biotech is scheduled for the week ahead. Formed by New Enterprise Associate's orphan drug accelerator Cydan, genetic disorder biotech Imara (IMRA) plans to raise $76 million at a $301 million market cap. The Boston-based company's sol...
The following slide deck was published by Satsuma Pharmaceuticals, Inc. in conjunction with this Read more ...
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief Executive Officer, will present a corporate update at the 9 th Annual ...
Gainers: Benitec Biopharma (NASDAQ: BNTC ) +51% . More news on: Benitec Biopharma Limited, Assertio Therapeutics, Inc., Ocwen Financial Corporation, Stocks on the move, , Read more ...
AbbVie (NYSE: ABBV ) initiated with Buy rating and $96 (11% upside) price target at Mizuho Securities. Shares up a fraction premarket. More news on: AbbVie Inc., Alkermes plc, BioLife Solutions, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Satsuma Pharmaceuticals Inc. Company Name:
STSA Stock Symbol:
NYSE Market:
DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. , a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc...
January 2024 PDUFA date expected If approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache Society ...
NEW YORK, NY / ACCESSWIRE / May 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hoth Therapeutics, Inc. (NASDAQ:HOTH)'s...